Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Fermenta Biotech's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Fermenta Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fermenta Biotech FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fermenta Biotech's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Fermenta Biotech's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fermenta Biotech (BOM:506414) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Fermenta Biotech and its competitors. According to the industry distribution chart, Fermenta Biotech ranks #235 out of 963 companies in the Drug Manufacturers industry, placing it in the top 24.4%.
Is Fermenta Biotech's FCF Margin % too high?
Fermenta Biotech's current FCF Margin % is 0.00%. Based on the distribution chart, Fermenta Biotech ranks #235 out of 963 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Fermenta Biotech has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fermenta Biotech's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Fermenta Biotech ranks #235 out of 963 companies for FCF Margin %. This places Fermenta Biotech in the top 24% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.58, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Fermenta Biotech and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fermenta Biotech's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fermenta Biotech stock overvalued right now?
Based on GuruFocus' analysis, Fermenta Biotech (BOM:506414) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹321.75, compared to a current price of ₹499.30 — trading 55.2% above its estimated fair value. The current FCF Margin % is 0.00%. Fermenta Biotech's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Fermenta Biotech (BOM:506414), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fermenta Biotech (BOM:506414) Overvalued in 2026?
Based on GuruFocus' analysis, Fermenta Biotech stock appears to be overvalued.
The current stock price of ₹499.30 is trading 55.2% above its estimated GF Value™ of ₹321.75.
GuruFocus considers Fermenta Biotech to be Significantly Overvalued.
Key valuation signals for BOM:506414:
FCF Margin %: 0.00%
GF Value™: ₹321.75 vs. price of ₹499.30 (55.2% above fair value)
No single metric tells the full story. See the BOM:506414 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fermenta Biotech Ltd is engaged in the business of manufacturing and marketing chemicals, bulk drugs, enzymes, pharmaceutical formulations, and environmental solution products and renting and selling properties. It is a manufacturer and supplier of Vitamin D and also supplies Penicillin G Amidase, CAL B Lipase, Polymer Supports, and enzyme technologies. The company operates in two segments namely Property and Bulk Drugs/Chemicals. The majority of the revenue comes from the Bulk Drug/Chemicals segment. Geographically, it caters to both domestic and international markets and generates maximum revenue from the Indian market.
65GF Score
Get the complete analysis for BOM:506414
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506414 has been successfully added to your 
